Skip to content
naulon
Not checkedNot checked for notices yet.

Orbital alveolar soft part sarcoma: clinicopathological characteristics and prognostic prediction

Te Zhang, Keyun Xue, Huijing Ye and 2 more

BMC Ophthalmology · 2025

doi:10.1186/s12886-025-04203-8 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Abstract Objective To explore the clinicopathological characteristics and prognosis of orbital alveolar soft part sarcoma (ASPS), providing a basis for its diagnosis and treatment. Methods Patients diagnosed with primary orbital ASPS at the Zhongshan Ophthalmic Center of Sun Yat-sen University from 2014 to 2024 were included. A retrospective analysis of clinical data, imaging findings, pathological features, immunohistochemistry results, etc., was conducted. Follow-up data were also analyzed. Results A total of 7 patients (7 eyes) were included in the study, consisting of 4 males and 3 females, aged between 2 and 47 years (median age 27 years), with follow-up period range from 16 to 201 months. Orbital protrusion was the most common presenting symptom (5/7), with one case involving invasion of the paranasal sinuses. During follow-up, all patients survived, and two patients experienced recurrence, all localized to the orbit. Recurrence was more common in younger patients, with an average recurrence time of 10 months post-surgery. High Ki67 expression was significantly associated with local recurrence (P = 0.047). Conclusion Primary orbital ASPS generally exhibits indolent biological behavior, and complete surgical excision can lead to long-term control. However, patients with high Ki67 expression should be closely monitored due to the higher risk of recurrence.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.